Scarica l'app Stockscreener
6.89
0.44%
0.03
Dopo l'orario di chiusura:
6.89
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$6.86
Aprire:
$6.76
Volume 24 ore:
893.52K
Relative Volume:
0.22
Capitalizzazione di mercato:
$310.19M
Reddito:
$123.87M
Utile/perdita netta:
$62.49M
Rapporto P/E:
4.127
EPS:
1.6695
Flusso di cassa netto:
$-87.53M
1 W Prestazione:
-16.38%
1M Prestazione:
-1.57%
6M Prestazione:
+104.45%
1 anno Prestazione:
+42.65%
Intervallo 1D:
$6.66
$7.04
Intervallo di 1 settimana:
$6.66
$8.38
Portata 52W:
$2.71
$8.85
Agenus Inc Stock (AGEN) Company Profile
Nome
Agenus Inc
Settore
Industria
Telefono
781-674-4410
Indirizzo
3 FORBES ROAD, LEXINGTON, MA
Compare AGEN vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AGEN
Agenus Inc
|
6.89 | 308.84M | 123.87M | 62.49M | -87.53M | 1.6695 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Agenus Inc Stock (AGEN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-04 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-07-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-07-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-07-18 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-06-06 | Iniziato | Robert W. Baird | Outperform |
| 2023-02-28 | Ripresa | H.C. Wainwright | Buy |
| 2022-09-28 | Iniziato | SMBC Nikko | Outperform |
| 2021-12-16 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-19 | Ripresa | B. Riley FBR | Buy |
| 2019-04-22 | Iniziato | B. Riley FBR | Buy |
| 2016-10-28 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2016-10-27 | Reiterato | Maxim Group | Buy |
| 2016-03-11 | Aggiornamento | Maxim Group | Hold → Buy |
| 2015-12-16 | Iniziato | Jefferies | Buy |
| 2015-10-27 | Downgrade | Maxim Group | Buy → Hold |
| 2015-07-27 | Reiterato | MLV & Co | Buy |
| 2015-06-11 | Iniziato | Oppenheimer | Outperform |
| 2015-01-12 | Reiterato | Maxim Group | Buy |
| 2015-01-09 | Reiterato | MLV & Co | Buy |
| 2015-01-09 | Reiterato | Maxim Group | Buy |
| 2014-12-19 | Reiterato | Maxim Group | Buy |
| 2014-05-08 | Reiterato | Maxim Group | Buy |
| 2014-03-14 | Reiterato | MLV & Co | Buy |
| 2013-10-08 | Reiterato | Maxim Group | Buy |
| 2012-01-05 | Iniziato | William Blair | Outperform |
| 2011-12-01 | Iniziato | Global Hunter Securities | Buy |
Mostra tutto
Agenus Inc Borsa (AGEN) Ultime notizie
BOT+BAL: Three-Year Overall Survival Data in Recurrent Ovarian Cancer – Agenus - Oncodaily
Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026 - BioSpace
Agenus to Present 3-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026 - Oncodaily
GOOG: Alphabet IncOrdinary SharesClass C Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Agenus Company Profile & Introduction - Moomoo
Agenus Stock Price Forecast. Should You Buy AGEN? - StockInvest.us
Agenus Inc (AGEN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Agenus to Participate in Upcoming September Investor Conferences - Business Wire
Immigrant Entrepreneur Garo H. Armen Of Agenus Inc. Riccardo Braschi (I0EURkuuPl) - Mshale
New Phase 2 NEST Results Support Neoadjuvant BOT+BAL in Colon Cancer – Agenus - Oncodaily
Agenus reports survival data for colorectal cancer treatment By Investing.com - Investing.com South Africa
Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism - Yahoo Finance
Agenus reports survival data for colorectal cancer treatment - Investing.com
Agenus Inc: Shareholders Revolt Over Executive Pay! My Thoughts. Tampa Bay Rays (VzxHMd1TNP) - Mshale
Agenus Inc.AGEN Stock Chart Technical Analysis For 09-21-2020 Sporting Cp (0os72ROBex) - Mshale
Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer - Yahoo Finance
Agenus Reports No Recurrences and Deep Pathologic Responses With Neoadjuvant BOT+BAL in Resectable Colon Cancer - Oncodaily
🔴 Agenus Inc. AGEN Stock Trading Facts 🔴 Gianna Nannini (9cYwfB9Crl) - Mshale
Agenus | Learn How I Turned $15,253 Into $1,613,442 Trading Biotech Stocks Donald Gibb (Gf1su3sDdD) - Mshale
AGEN Stock Analysis | Agenus Inc Stock Update & Chart Breakdown Traffic Stop (vDz5v0ltyg) - Mshale
Bold Move By Agenus: Cutting Costs By 60% To Focus On Groundbreaking Cancer Treatments Nikoloz Basilashvili (41VwNJliWR) - Mshale
Why Agenus (AGEN Stock) Just Rocketed Up—Buy Now Or Too Late? Cigarette (l3DDhgoK4D) - Mshale
Insider Trading AGEN Agenus Inc 2021 05 18 Blowing Dust Advisory (aETsN3n1J0) - Mshale
Agenus Inc AGEN CEO Garo Armen On Q4 2019 Results David Muir (NjcFXnx049) - Mshale
Agenus Inc (AGEN) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
AGEN Stock TUESDAY MADNESS! (news Update) Agenus Stock Analysis Best Broker Review Challenge Cup Final 2026 (5MyfQl06Kh) - Mshale
Agenus Inc. (AGEN) Latest Stock News & Headlines - Yahoo Finance
Agenus extends $24.75 million loan maturity, adjusts payment terms with Ocean 1181 - Investing.com
Form 8K Agenus Inc For: 18 August By Investing.com - Investing.com South Africa
Agenus Extends $24.75M Term Loan to 2029 at 13% With Ocean 1181; Partly Payable in Stock - TradingView
Agenus (NASDAQ: AGEN) to pay part of 13% loan interest in stock - Stock Titan
Agenus Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
AGEN Q2 2026 Earnings: EPS Misses Estimates by 119.61% as Shares Slide 2.32%EBITDA Estimate Trend - Vinanet
AGENUS INC SEC Filing (Aug 17, 2026) - Stock Titan
Agenus Puts Its BOT+BAL Cancer Combo To The Test - Finimize
Renaissance Technologies LLC Sells 257,900 Shares of Agenus Inc. $AGEN - MarketBeat
HC Wainwright Estimates Agenus' Q3 Earnings (NASDAQ:AGEN) - MarketBeat
Agenus grants CEO Garo Armen 1,971,500 performance-based stock options at $7.78 per share - Bitget
Agenus (NASDAQ: AGEN) awards 1.97M performance-tied stock options to CEO - Stock Titan
Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL S - The National Law Review
Form 8K Agenus Inc For: 11 August By Investing.com - Investing.com South Africa
Agenus appoints Marco Tullio Marcucci to board of directors By Investing.com - Investing.com Nigeria
Agenus appoints Marco Tullio Marcucci to board of directors - Investing.com
Agenus Inc Azioni (AGEN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):